Financial Lp Hrt Sells 42,411 Shares of Profusa (NASDAQ:PFSA) Stock

Profusa, Inc. (NASDAQ:PFSA) major shareholder Financial Lp Hrt sold 42,411 shares of the stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $0.89, for a total transaction of $37,745.79. Following the sale, the insider directly owned 74,198 shares of the company’s stock, valued at $66,036.22. This represents a 36.37% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Wednesday, August 12th, Financial Lp Hrt acquired 5,585 shares of Profusa stock. The shares were bought at an average price of $0.96 per share, for a total transaction of $5,361.60.
• On Tuesday, August 4th, Financial Lp Hrt acquired 1,368 shares of Profusa stock. The stock was bought at an average cost of $0.95 per share, for a total transaction of $1,299.60.
• On Monday, August 3rd, Financial Lp Hrt bought 14,556 shares of Profusa stock. The stock was bought at an average cost of $0.96 per share, with a total value of $13,973.76.
• On Wednesday, July 29th, Financial Lp Hrt bought 1,310 shares of Profusa stock. The shares were purchased at an average price of $1.01 per share, with a total value of $1,323.10.

Profusa Price Performance

Shares of PFSA traded down $0.06 during midday trading on Friday, hitting $0.90. The stock had a trading volume of 46,269 shares, compared to its average volume of 223,125. The company has a 50 day simple moving average of $2.85 and a two-hundred day simple moving average of $25.06. Profusa, Inc. has a twelve month low of $0.81 and a twelve month high of $1,297.50. The firm has a market cap of $170,050.00, a price-to-earnings ratio of -0.00 and a beta of 0.52.

Profusa shares are set to reverse split on the morning of Monday, August 17th. The 1-4 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Sunday, August 16th.

Analysts Set New Price Targets

Several research analysts have recently weighed in on PFSA shares. Wall Street Zen upgraded shares of Profusa from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 18th. Weiss Ratings reissued a “sell (e+)” rating on shares of Profusa in a research note on Wednesday, June 24th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Sell”.

About Profusa

Profusa develops implantable, tissue-integrated biosensors and associated reader technology designed to provide continuous, real-time monitoring of physiological biomarkers. Its platform uses a biocompatible, porous hydrogel sensor that is placed under the skin via a minimally invasive procedure and becomes perfused with tissue; an external optical reader interrogates the sensor to convert fluorescent or optical signals into quantitative measurements such as local tissue oxygen levels. The company’s approach emphasizes long-duration sensing from a single implanted device rather than repeated spot measurements.

The technology is being positioned to support a range of clinical and commercial applications, including chronic disease management, wound and post-surgical monitoring, and clinical research where continuous molecular-level data can improve decision-making.